.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2015 for a whopping $43 ...
.On the heels of a phase 3 win that neglected to thrill capitalists, Ironwood Pharmaceuticals is bac...
.Do not cease Monte Rosa Rehabs now. The Boston-based biotech is actually having a ball after author...
.Accept to recently's Chutes & Ladders, our roundup of significant leadership hirings, firings as...
.Celebrating his company's upsized initial public offering (IPO), Septerna chief executive officer J...
.AbbVie has returned to the source of its own antipsychotic giant Vraylar in search of another smash...
.GenSight Biologics is weeks away from lacking cash. Once again. The biotech only has adequate cash ...
.Monopar Rehabs is recuperating a drug coming from the scrap heap of AstraZeneca's unusual illness p...
.Along with new records out on Arcus Biosciences' speculative HIF-2a inhibitor, one team of professi...
.After developing a genetics therapy collaboration with Dyno Rehabs in 2020, Roche is back for more....